Glioblastoma Multiforme Treatment (GBM) Market
Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
Press Release :
Increased Prevalence of the Disease Boosts Glioblastoma Multiforme Treatment Market
Glioblastoma multiforme refers to those malignant tumors that affect the spine or brain. This type of tumors grows and expands at a very rapid pace and it often creates extreme pressure. Glioblastoma multiforme is one of the most malignant and common type of the glial tumors. This type of tumor develops from star-shaped glial cells (oligodendrocytes and astrocytes), which encourages the overall health of the nerve cells inside the brain. Global glioblastoma multiforme treatment market is likely to gather momentum from the rising incidences of the disease across the globe.
In accordance with the U.S. National Cancer Institute, glioblastoma multiforme is one of the most aggressive types of cancer in the brain and it represents nearly 60% to 75% of all astrocytoma and 15.4% of all the primary brain tumors. This type of tumors exhibits rapid spread of benign cells within the organ.
Inability of Treatment Methods to Prolong Life Span of Patients to Spell Market Growth
The global glioblastoma multiforme treatment market is likely to observe substantial growth over the tenure of assessment due to expanding base of geriatric population and increased prevalence of oncology diseases.
Symptoms of glioblastoma multiforme comprise the following
- Blurred vision
- Personality changes
Treatments of glioblastoma multiforme comprise surgery, chemotherapy, and radiation. However, the presence of treatment options fails to expand the overall survival rate of glioblastoma multiforme-stricken patients. Despite radiotherapy and chemotherapy, the survival rate of the patients does not increase. This factor is expected to encourage growth of the global glioblastoma multiforme treatment in the years to come.
In addition to that, glioma stem cells are capable of resisting the usual methods of treatments, which further drives the growth of the global glioblastoma multiforme treatment market over the assessment. Increased research and development in molecular biotechnology and gene therapy is further expected propel growth of the global glioblastoma multiforme treatment market.
Glioblastoma multiforme (GBM) is the most frequent and lethal primary brain tumor in adults. The current treatment modalities available in the market are surgical resection followed by chemotherapy and radiotherapy, that unable to increase the overall survival of patient. The main reason behind inability of these treatments are frequent recurrence, invasiveness of GBM and resistance of glioma stem cells to conventional treatments. Therefore, novel alternative treatment strategies are desperately needed and pipeline of GBM already involves a mix of biological, immunotherapy, small molecules and other types of therapeutics. Recent advancements in molecular biology and gene technology have provided attractive novel treatment possibilities for the patients diagnosed with GBM.
- Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs
- Bevacizumab (Avastin)
- Temozolomide (Temodar and Temodal and Temcad)
- Carmustine (BiCNU)
- Global Glioblastoma Treatment Market Revenue and Forecast, by Geography
- North America
- Asia Pacific
- Rest of the World
- Global Pipeline Review of Glioblastoma Treatment
- Late Stage (Phase III)
- Rindopepimut (CDX-110)
- Early Stage (Phase I, II and Pre clinical)